⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21142491 | 0.76 | — | — | |
| SCHEMBL9980167 | 0.75 | — | — | |
| SCHEMBL2757040 | 0.73 | — | — | |
| SCHEMBL17885802 | 0.73 | — | — | |
| SCHEMBL21146104 | 0.67 | — | — | |
| SCHEMBL21973491 | 0.64 | — | — | |
| SCHEMBL18463012 | 0.62 | — | — | |
| SCHEMBL15462352 | 0.60 | L3MBTL1 (0.31) | — | |
| SCHEMBL9977065 | 0.60 | L3MBTL1 (0.31) | — | |
| SCHEMBL17765546 | 0.60 | L3MBTL1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738013-B2 | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220117952-A1 | METHODS FOR TREATING HEPATITIS B VIRUS INFECTIONS USING NS5A, NS5B OR NS3 INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-9303061-B2 | Spiro compounds as Hepatitis C virus inhibitors | Sunshine Luke Pharma Co., Ltd. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-20150307509-A1 | FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-29 | — | — | US | disclosed |
| US-20150299215-A1 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |